Metronidazole 250 mg Tablet: A no-nonsense look at an industry workhorse

If you’ve worked in pharmacy procurement or clinical operations for any length of time, you’ve seen metronidazole bv tablets on countless order sheets. It’s one of those essential antimicrobials that keeps showing up—for good reason. In practice, it targets anaerobic bacteria and protozoa with dependable efficiency, and, yes, many customers say it’s fast-acting when used appropriately under professional supervision. To be honest, the “boring reliability” here is exactly what clinicians and supply managers like.

Industry trends

Three things are shaping demand right now: antimicrobial stewardship (fewer, smarter prescriptions), stable API sourcing (nitroimidazole supply lines have tightened in some seasons), and serialization/track-and-trace. Surprisingly, despite market squeezes, quality-focused manufacturers continue to deliver consistent batches, leaning into GMP upgrades and tighter impurity controls. It seems that the bar keeps rising—and that’s good for end users.

Product overview and applications

Metronidazole 250 mg Tablet is positioned for anaerobic bacterial and protozoal infections across gastrointestinal, dental/oral, and certain gynecological indications—always per local labeling and a licensed professional’s direction. In veterinary settings, it’s commonly discussed for GI infections in companion animals as well. When folks say metronidazole bv tablets, they’re typically thinking reliability, inflammation reduction, and solid infection control in appropriate cases.

Technical specs (typical)

Product Name	Metronidazole 250 mg Tablet
API Strength	250 mg metronidazole (nitroimidazole class)
Excipients (typical)	Microcrystalline cellulose, starch, povidone, magnesium stearate (formulations may vary)
Release Specs	Assay ≈ 98.5–101.5%; Dissolution ≥ Q in 30 min; Content uniformity per USP/EP
Packaging	Blisters (10s/20s) or bottles (≈100/500); real-world options may vary by market
Shelf Life	≈ 24–36 months, store below 25°C, dry conditions
Certifications	GMP-compliant production; ISO 9001 for QMS (supplier-dependent)

Manufacturing and testing flow

Materials: qualified metronidazole API (CoA-verified), pharma-grade excipients. Methods: raw material ID (IR), blending, wet granulation or direct compression, tablet pressing, optional film coating, blistering/bottling, serialization. Testing: HPLC assay, dissolution (USP ), content uniformity, related substances per ICH Q3B, microbial limits, stability (ICH Q1A). Service life is essentially the labeled shelf life validated in ICH zone-appropriate studies.

Where it fits

• Hospitals and clinics standardizing anaerobic coverage formulary
• Dental practices addressing anaerobic oral pathogens
• Veterinary clinics handling GI infections (under vet guidance)
• Distributors needing stable, serialized supply with predictable QC

Customer feedback? “Solid, consistent lot-to-lot,” one buyer told us; another mentioned fewer backorders than comparable SKUs—anecdotal but interesting.

Vendor comparison (indicative)

Vendor	QC/Certs	Lead Time	Customization	Notes
Hebei Manufacturer (Origin: Room 2210, Building A, Yihongxia, 298 Zhonghuabei Street, Xinhua District, Shijiazhuang, Hebei, China)	GMP, ISO 9001	≈ 3–5 weeks	Blister count, bottle size, private label	Stable API sourcing; flexible MOQs
Global Generic Supplier	GMP, some EU GMP sites	≈ 4–8 weeks	Limited packs, multi-language inserts	Broad market registrations
Regional OEM Partner	GMP	≈ 2–4 weeks	High customization	Best for niche SKUs

Customization and documentation

Options often include 250 mg or 500 mg strengths, artwork/label localization, blister/bottle counts, and veterinary vs. human-use labeling per jurisdiction. Expect the usual pack: CoA, MSDS, stability summaries, method validation, and, where relevant, bioequivalence data. It’s worth asking for recent stability pulls—real-world use may vary and fresh data helps.

Case snapshots

• Regional distributor reduced stockouts by 38% after switching to metronidazole bv tablets from a Hebei line with tighter release windows.
• A dental network cited consistent dissolution profiles (Q met at 30 min) across three lots—less variance in chair-time planning.

Note: Use only as directed by a licensed professional and per local regulations and labeling. This article is informational; it’s not medical advice.

References

1. CDC. STI Treatment Guidelines: Bacterial Vaginosis – Metronidazole recommendations. https://www.cdc.gov/std/treatment-guidelines/bv.htm
2. WHO Model List of Essential Medicines – Metronidazole. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
3. USP–NF Monograph: Metronidazole Tablets; USP General Chapters Dissolution, Uniformity of Dosage Units. https://www.usp.org
4. ICH Guidelines: Q1A(R2) Stability Testing, Q3B(R2) Impurities in New Drug Products, Q7 GMP for APIs. https://www.ich.org